Pharmasset, Inc. (Nasdaq: VRUS) announced that the enrollment of Cohort 2, led by its partner Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY), will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) [...]

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that enrollment has been completed ahead of schedule in the Company’s phase 2 clinical trial for RP101 in patients with late-stage pancreatic cancer. Results from a previous phase 1 study in 22 late-stage pancreatic cancer [...]